The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The Advantages and Challenges of Using Endolysins in a Clinical Setting
Open accessAbstract
Antibiotic-resistant pathogens are increasingly more prevalent and problematic. Traditional antibiotics are no longer a viable option for dealing with these multidrug-resistant microbes and so new approaches are needed. Bacteriophage-derived proteins such as endolysins could offer one effective solution. Endolysins are bacteriophage-encoded peptidoglycan hydrolases that act to lyse bacterial cells by targeting their cell’s wall, particularly in Gram-positive bacteria due to their naturally exposed peptidoglycan layer. These lytic enzymes have received much interest from the scientific community in recent years for their specificity, mode of action, potential for engineering, and lack of resistance mechanisms. Over the past decade, a renewed interest in endolysin therapy has led to a number of successful applications. Recombinant endolysins have been shown to be effective against prominent pathogens such as MRSA, Listeria monocytogenes, Staphylococcus strains in biofilm formation, and Pseudomonas aeruginosa. Endolysins have also been studied in combination with other antimicrobials, giving a synergistic effect. Although endolysin therapy comes with some regulatory and logistical hurdles, the future looks promising, with the emergence of engineered “next-generation” lysins. This review will focus on the likelihood that endolysins will become a viable new antimicrobial therapy and the challenges that may have to be overcome along the way.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Origins and evolution of antibiotic resistance
Davies, J., & Davies, D. (2010) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00016-10 · Cited by 5,784
Bacteriophage resistance mechanisms
Labrie, S. J., Samson, J. E., & Moineau, S. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2315 · Cited by 2,397
Antibiotics: past, present and future
Hutchings, M. I., Truman, A. W., & Wilkinson, B. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.10.008 · Cited by 2,370
Lysogenic Conversion by a Filamentous Phage Encoding Cholera Toxin
Waldor, M. K., & Mekalanos, J. J. (1996) · Science · doi:10.1126/science.272.5270.1910 · Cited by 1,879
Origins and evolution of antibiotic resistance.
DAVIES, J. E. (1996) · PubMed · Cited by 941
Langdon, A., Crook, N., & Dantas, G. (2016) · Genome Medicine · doi:10.1186/s13073-016-0294-z · Cited by 912
From bacterial killing to immune modulation: Recent insights into the functions of lysozyme
Ragland, S. A., & Criss, A. K. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006512 · Cited by 877
A century of the phage: past, present and future
Salmond, G. P. C., & Fineran, P. C. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3564 · Cited by 823
Bacteriophage Endolysins as Novel Antimicrobials
Schmelcher, M., Donovan, D. M., & Loessner, M. J. (2012) · Future Microbiology · doi:10.2217/fmb.12.97 · Cited by 785
Cited by
Muteeb, G., Rehman, M. T., Shahwan, M., & Aatif, M. (2023) · Pharmaceuticals · doi:10.3390/ph16111615 · Cited by 1,215
Elfadadny, A., Ragab, R. F., AlHarbi, M., Badshah, F., Ibáñez-Arancibia, E., Farag, A., Hendawy, A. O., De los Ríos-Escalante, P. R., Aboubakr, M., Zakai, S. A., et al. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1374466 · Cited by 340
Nanozybiotics: advancing antimicrobial strategies through biomimetic mechanisms
Zhou, C., Wang, Q., Cao, H., Jiang, J., & Gao, L. (2024) · Advanced Materials · doi:10.1002/adma.202403362 · Cited by 114
Kim, K., Jang, H., Kim, E., Kim, H., & Sung, G. Y. (2023) · Experimental Dermatology · doi:10.1111/exd.14940 · Cited by 24
Metadata
- Authors
- Murray, E., Draper, L. A., Ross, R. P., & Hill, C.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2021-04-15
- Volume
- 13
- Issue
- 4
- Pages
- 680
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W3152895331
- Cited by
- 263
- References
- 52
- FWCI
- 20.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Advantages and Challenges of Using Endolysins in a Clinical Setting. https://app.cochat.ai/papers/10.3390/v13040680
- The paper
- Murray, E., Draper, L. A., Ross, R. P., & Hill, C. (2021). The Advantages and Challenges of Using Endolysins in a Clinical Setting. Viruses. https://doi.org/10.3390/v13040680
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.